JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors
Open Access
- 12 November 2019
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 3 (6), e313
- https://doi.org/10.1097/hs9.0000000000000313
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemiaHaematologica, 2015
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisHaematologica, 2015
- Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemiaBlood, 2015
- Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responsesBlood, 2015
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia VeraThe New England Journal of Medicine, 2015
- JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse modelBlood, 2014
- The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapseHaematologica, 2014
- Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemiaLeukemia, 2014
- JAK/STAT signaling in hematological malignanciesOncogene, 2012
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemiaNature, 2012